NKA Bio is developing new medicines to improve critical care. Our lead product is NKA01, a temperature-stable antibody for trauma patients. When you are severely injured, it is a race against time to get to surgery. The average person dies 8 minutes before lifesaving treatment can be delivered. But in the future, when minutes count, our antibody will buy hours. At NKA Bio, our treatment presses pause on death. With an injection of NKA01 by EMS, our drug could buy more time for transport and lifesaving surgery.
| Website | https://www.nkabio.com |
| Employees | 7 (5 on RocketReach) |
| Founded | 2023 |
| Phone | +1 443-465-7702 |
| Industry | Biotechnology Research |
| Keywords | Critical Care, Biotechnology, Trauma Treatment, Pharmaceutical, Healthcare, Therapeutics, Antibody Therapeutics, Patient Care, Emergency Medicine, Biopharma, Drug Development, Medicine, Medical Research, Life Sciences, New Medicines, Surgical Care, Immunotherapy, Clinical Trials, Treatment |
Looking for a particular NKA Bio employee's phone or email?
Lewis Hibbs is the Co-founder and CTO of NKA Bio.
5 people are employed at NKA Bio.